WSK-V108E

The objective of this study was to evaluate the safety, tolerability, and immunogenicity of the novel drug WSK-V108E in patients with mild to moderate facial acne (acne vulgaris) for the first time. Using a randomized, double-blind design with a placebo control, the study focused on observing whether adverse reactions occurred in subjects, whether the drug was well tolerated, and whether immune changes such as antibody production occurred. In short, this is an early-stage clinical study that lays an important safety foundation for subsequent efficacy research.